Abstract
Drug-eluting stents (DES) have become routine therapy in clinical practice because restenosis is significantly reduced in patients treated with these devices. New generations of DES bearing newer antiproliferative drugs have been developed. Sirolimus was the first antiproliferative drug eluted by a DES (SES) while zotarolimus represents a sirolimus-derived, newer antiproliferative drug borne by a different kind of DES (ZES). This report describes two cases of different vascular response to concurrent side by side implantation of SES and ZES in the same vessel and highlights significant early restenosis of ZES as compared with SES.
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / instrumentation*
-
Cardiovascular Agents / administration & dosage*
-
Coronary Angiography
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / therapy*
-
Coronary Restenosis / diagnostic imaging
-
Coronary Restenosis / etiology*
-
Coronary Restenosis / therapy
-
Drug Therapy, Combination
-
Drug-Eluting Stents / adverse effects*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Platelet Aggregation Inhibitors / therapeutic use
-
Prosthesis Design
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives*
-
Treatment Outcome
Substances
-
Cardiovascular Agents
-
Platelet Aggregation Inhibitors
-
zotarolimus
-
Sirolimus